

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Claims 1-81 (Cancelled)

82. (New) An isolated polypeptide comprising:

- a) the amino acid sequence of SEQ ID NO. 2 or
- b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2;
wherein said sequence comprises a C122S SNP.

83. (New) A composition comprising the polypeptide of claim 82 and at least one excipient.

84. (New) The composition of claim 83, wherein said excipient is a pharmaceutically acceptable excipient.

85. (New) The composition of 84, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.

86. (New) A pharmaceutical composition comprising the polypeptide of claim 82 and a pharmaceutically acceptable excipient.

87. (New) The pharmaceutical composition of 86, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.

88. (New) An isolated polypeptide comprising an amino acid sequence at least 95% identical to
- a) the amino acid sequence of SEQ ID NO. 2 or
 - b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2;
wherein said sequence comprises a C122S SNP and said polypeptide exhibits at least one antiviral activity, antiproliferative activity, or immunomodulatory activity;
wherein said antiviral activity is against vesicular stomatitis virus or encephalomyocarditis virus;
wherein said antiproliferative activity is against TF-1 or Daudi Burkitt's cell line;
wherein said immunomodulatory activity is dendritic cell maturation, cytokine release by monocytes, CD4+ T-lymphocytes, or CD8+ T-lymphocytes.
89. (New) The polypeptide of claim 88, wherein said amino acid sequence is at least 97% identical to the amino acid sequence SEQ ID NO: 2.
90. (New) The polypeptide of claim 88, wherein said amino acid sequence is at least 99% identical to the amino acid sequence SEQ ID NO: 2.
91. (New) The polypeptide of claim 88, wherein said amino acid sequence is at least 97% identical to the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2.
92. (New) The polypeptide of claim 88, wherein said amino acid sequence is at least 99% identical to the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2.
93. (New) A composition comprising the polypeptide of claim 88 and at least one excipient.
94. (New) The composition of claim 93, wherein said excipient is a pharmaceutically acceptable excipient.

95. (New) The composition of 94, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
96. (New) A pharmaceutical composition comprising the polypeptide of claim 88 and a pharmaceutically acceptable excipient.
97. (New) The pharmaceutical composition of 96, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.